Marco Roffi
Overview
Explore the profile of Marco Roffi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
342
Citations
17157
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iglesias J, Assouline B, Chatelain Q, Musayeb Y, Degrauwe S, Roffi M
J Am Heart Assoc
. 2025 Mar;
:e036642.
PMID: 40079326
Background: P2Y inhibitor-based single antiplatelet therapy (SAPT) after drug-eluting stent implantation reduces major bleeding without increasing the risk of major adverse cardiovascular and cerebral events compared with 12-month dual antiplatelet...
2.
Tacchini V, Gkotsoulia C, Barrier A, Johner N, Shah D, Burri H, et al.
Rev Med Suisse
. 2025 Jan;
21(902):119-125.
PMID: 39846095
Atrial fibrillation (AF) is common and its treatment is complex. The new European guidelines emphasize a patient-centered approach, considering the risk factors that contribute to AF and their management in...
3.
Barrier A, Tacchini V, Gkotsoulia C, Mauler-Wittwer S, Degrauwe S, Iglesias J, et al.
Rev Med Suisse
. 2025 Jan;
21(900-1):13-16.
PMID: 39812278
The year 2024 has witnessed substantial advancements in interventional cardiology, encompassing both coronary and structural interventions.In coronary field, trials have explored percutaneous innovations for coronary lesions, strategies for managing post‑infarction...
4.
5.
Planchat A, Gencer B, Degrauwe S, Musayeb Y, Roffi M, Iglesias J
Front Cardiovasc Med
. 2024 Dec;
11:1436332.
PMID: 39650149
Diabetes mellitus (DM) promotes atherosclerosis, leading to increased risk for cardiovascular morbidity and mortality. Diabetics represent a challenging subset of patients undergoing percutaneous coronary intervention (PCI) or who have experienced...
6.
Bengueddache-Schweblin C, Zbinden S, Roffi M, Righini M, Glauser F
Rev Med Suisse
. 2024 Dec;
20(898):2287-2291.
PMID: 39639616
Systemic thrombolysis is the first-line treatment for patients with high-risk pulmonary embolism or with haemodynamic deterioration on anticoagulation alone; however, it is associated with a high bleeding risk. Mechanical thrombectomy...
7.
Roffi M, Landi A, Heg D, Frigoli E, Chalkou K, Chevalier B, et al.
JACC Cardiovasc Interv
. 2024 Nov;
17(22):2664-2677.
PMID: 39603779
Background: Abbreviated antiplatelet therapy (APT) reduces bleeding without increasing ischemic events in largely unselected high bleeding risk (HBR) patients undergoing percutaneous coronary intervention (PCI). Diabetes mellitus (DM) is associated with...
8.
Stahli B, Schindler M, Schweiger V, Cammann V, Szawan K, Niederseer D, et al.
Eur J Clin Invest
. 2024 Oct;
54(12):e14317.
PMID: 39397275
Background: The clinical relevance of cardiac troponin (cTn) elevation in takotsubo syndrome (TTS) remains uncertain. The present study sought to investigate the role of cardiac troponin (cTn) elevations in mortality...
9.
Johner N, Gencer B, Roffi M
Eur J Clin Invest
. 2024 Sep;
54(12):e14309.
PMID: 39257189
Background: Beta-blocker therapy, a treatment burdened by side effects including fatigue, erectile dysfunction and depression, was shown to reduce mortality and cardiovascular events after acute coronary syndromes (ACS) in the...
10.
Baroz A, Musayeb Y, Degrauwe S, Roffi M, Iglesias J
Rev Med Suisse
. 2024 Sep;
20(885):1560-1566.
PMID: 39238459
Vasospastic angina (VSA) was first described in 1959 by Myron Prinzmetal as "the variant form of angina pectoris" on the sole basis of medical history and ECG. This condition is...